[Type I glycogenosis: extending therapy with uncooked cornstarch].

Area of Science:

• Biochemistry
• Pediatric Endocrinology
• Metabolic Disorders

Background:

• Glycogenosis type I (GSD I) is a metabolic disorder characterized by impaired glucose production.
• Conventional treatment involves continuous glucose supply, often via nocturnal gastric drip feeding with maltodextrin.
• Maintaining stable blood glucose and lactate levels is crucial for managing GSD I.

Purpose of the Study:

• To evaluate the efficacy of uncooked cornstarch as an alternative or adjunct therapy for GSD I.
• To assess the impact of uncooked cornstarch on metabolic control in pediatric patients with GSD I.
• To determine if uncooked cornstarch can improve fasting tolerance and glucose stability.

Main Methods:

• Study involved 12 pediatric patients (0.9-16 years) with GSD I.
• Compared conventional treatment (maltodextrin drip feeding) with uncooked cornstarch therapy.
• Administered uncooked cornstarch in varying doses (1.4-2.0 g/kg or 2-3 g/kg every 6h) and frequencies.
• Monitored blood lactate and 24-h urine lactate/creatinine ratios for metabolic control.

Main Results:

• Uncooked cornstarch provided similar metabolic control to conventional treatment in 4 older patients (10-16 years).
• A 7-year-old patient with GSD Ib achieved stable blood glucose levels, enabling school attendance.
• A 2-year-old patient maintained constant blood glucose levels with regular cornstarch administration, facilitating emigration.
• Therapy with uncooked cornstarch demonstrated suitability for augmenting GSD I management.

Conclusions:

• Uncooked cornstarch is a viable therapeutic option for managing glycogenosis type I.
• This dietary approach can improve glucose homeostasis and fasting tolerance in pediatric GSD I patients.
• Uncooked cornstarch therapy offers flexibility and potential benefits for specific GSD I patient populations.